Probiodrug AG, a German specialist in Alzheimer’s disease, is planning to make an initial public offering of its shares on the Amsterdam Euronext exchange to support development of a drug that targets small amyloid-beta aggregates. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
